Pharmacia & Upjohn Drops MS Therapy
Pharmacia & Upjohn have stopped its clinical trials program for Linomide(roquinimex) for the treatment of multiple sclerosis due to an unexpected incidence of cardiovascular side effects.
Eight cases of (nonfatal) myocardial infarction were reported in two Phase III trials of Linomide, and although a third trial had no reports of MI, the company said that these observations had tipped the risk-benefit balance for the drug so that it was no longer an acceptable treatment for MS.
Linomide was originally developed for leukemia, but this indication was dropped when MS was seen as a more commercially-attractive opportunity. The drug has also been tested in diabetes, and P&U is reviewing the data from these studies to look for cardiovascular effects and to see if there is any future for it. Meantime, there has been better news for P&U in the UK (see page 28).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze